Abstract
Purpose: We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial. In the primary, conventional analyses, the predefined statistical significance thresholds were not reached. We conducted a pre-planned Bayesian analysis to facilitate probabilistic interpretation.
Methods: We analysed outcome data within 90 days in the intention-to-treat population (data available in 967 to 982 patients) using Bayesian models with various sensitivity analyses. Results are presented as median posterior probabilities with 95% credible intervals (CrIs) and probabilities of different effect sizes with 12 mg dexamethasone.
Results: The adjusted mean difference on days alive without life support at day 28 (primary outcome) was 1.3 days (95% CrI -0.3 to 2.9; 94.2% probability of benefit). Adjusted relative risks and probabilities of benefit on serious adverse reactions was 0.85 (0.63 to 1.16; 84.1%) and on mortality 0.87 (0.73 to 1.03; 94.8%) at day 28 and 0.88 (0.75 to 1.02; 95.1%) at day 90. Probabilities of benefit on days alive without life support and days alive out of hospital at day 90 were 85 and 95.7%, respectively. Results were largely consistent across sensitivity analyses, with relatively low probabilities of clinically important harm with 12 mg on all outcomes in all analyses.
Conclusion: We found high probabilities of benefit and low probabilities of clinically important harm with dexamethasone 12 mg versus 6 mg daily in patients with COVID-19 and severe hypoxaemia on all outcomes up to 90 days.
Trial registration: ClinicalTrials.gov NCT04509973 .
Keywords: Bayesian analysis; COVID-19; Corticosteroids; Critical illness; Hypoxaemia.
【저자키워드】 COVID-19, Critical illness, Corticosteroids, hypoxaemia, Bayesian analysis, 【초록키워드】 Dexamethasone, coronavirus disease, Bayesian, Mortality, Trial, randomised, hospital, risk, outcome, COVID, Probability, International, Patient, Interpretation, hypoxaemia, threshold, patients, Support, Primary outcome, intention-to-treat population, statistical significance, Sensitivity analyses, mean difference, posterior probability, effect size, benefit, Bayesian model, Result, blinded, clinically, conducted, analysed, facilitate, median, adjusted, reached, analyses, interval, CrI, days alive, patients with COVID-19, serious adverse reaction, 【제목키워드】 Trial, COVID, patients with COVID-19,